Background: Simple, affordable CD4 cell counting is urgently needed to stage and
INTRODUCTION
As the cost of antiretroviral therapy (ART) continues to fall, HIV treatment has been made available to nearly two million people worldwide. 1 Nevertheless, delivering antiretroviral-based care on a global scale, and reaching an additional four million people suffering from advanced HIV infection, presents critical challenges. Especially in subSaharan Africa, the delivery of HIV care is compromised by under-resourced facilities and severe shortages of skilled health workers. 2 Deficiencies in laboratory infrastructure have become particularly critical bottlenecks to the scale-up of HIV care programs. prophylaxis, and to increase patient monitoring intensity, respectively. 4 Given the widespread lack of viral load testing, WHO also recommends that changes in CD4 counts be used as the primary means to monitor patient responses to ART.
However, the standard laboratory equipment and kits used for CD4 counting have limited penetration in resource-poor settings, despite ongoing international efforts to extend ART in these areas. A severe shortage of trained laboratory technicians may be the major barrier. Flow cytometers, including smaller, single-purpose CD4 counting devices developed recently, require trained laboratory technicians to handle and process samples, and to analyze and report data. [5] [6] [7] [8] Because flow cytometry-based CD4 counting is beyond the reach of so many HIV-infected people, the WHO and others have urged the development of simple-to-use, point-of-care CD4 count assays designed for resourcelimited settings. [9] [10] [11] To address the need for CD4 counting devices that are simple to use and inexpensive, we recently reported a new microfluidic system for isolating pure populations of CD4+ T cells that requires fingerstick samples of whole blood, with no sample processing or specific labelling. 12 This technology enables specific capture of CD4+ T lymphocytes with high efficiency; key elements of the approach include: (1) a microfluidic channel functionalized with immobilized anti-CD4 antibodies for affinity isolation of CD4+ cells from unprocessed whole blood; (2) microliter volumes of sample and wash buffer; and (3) controlled sample and wash buffer delivery for efficient CD4+ T cell capture with minimal monocyte contamination. CD4 counts are obtained by enumerating all cells isolated from a 10 microliter volume of blood, using a standard light microscope. In this paper, we evaluate the performance of our microchip CD4 counting system using whole blood samples from 49 HIV-infected subjects at different stages of disease. We compare both the accuracy and simplicity of CD4 counts obtained from the microchip system with standard flow cytometric measurements.
METHODS

Device Fabrication
Microfluidic cell isolation devices for CD4+ T capture were fabricated in poly (dimethyl) The device schematic and a photograph are depicted in Figure 1 .
Study Subjects and Clinical CD4 Counts
The study enrolled 49 HIV-infected and four HIV-negative adult subjects. All subjects 
CD4 Counts by Microchips
A 10 µl aliquot of whole blood from HIV-infected subjects was introduced into the microchip at 5 µl/min, followed by 60 • µl of PBS containing 1% BSA (w/v) and 1mM
EDTA at a flow rate of 20 µl/min. Total assay time was 5 minutes. Cells adherent to the surface were counted by placing a field finder under the chambers and counting all cells isolated in the device using the 10X objective of an inverted microscope (Nikon Eclipse TE2000, Nikon, Japan).
Statistics and Data Analysis
The accuracy of microchip-based CD4 counting system was determined by comparing results to parallel samples processed by flow cytometry, using Passing-Bablok regression analysis and the Bland-Altman methods comparison approach. 16, 17 Results were analyzed using the Analyze-It Software package extension for Microsoft Excel.
RESULTS
The microchip CD4 counting device used in the assay is depicted in Figure 1 . This simple system requires no red blood cell lysing, external reagents, or sample processing. CD4 cell counts are obtained by introducing ten microliters of whole blood, followed by 60 microliter of PBS wash. Retained CD4 cells are then counted under a standard light microscope.
Using this device, we obtained microchip CD4 counts in whole blood samples from 49
HIV-positive adult subjects. All subjects had parallel CD4 count results obtained by standard 4-color flow cytometry. Demographic characteristics of the study subjects are shown in Table 1 .
The agreement between the two CD4 counting methods over the entire CD4 count range is shown in Figure 2 . We observed a close correlation between the two methods for CD4 (Table 2 ).
In our study population of HIV-infected adults, 7 of 49 subjects had CD4 cell counts above 800 cells/µL. In these subjects, microdevice CD4 cell counts are lower than those obtained by flow cytometry. We confirmed that this observation was independent of HIV status by evaluating whole blood samples obtained from four healthy, HIV-negative subjects with CD4 counts above 800 cells/µL (Table 3) .
DISCUSSION
We evaluated the performance of a simple, label-free, whole blood CD4+ T cell counting device using cell affinity chromatography in a microfluidic format. We have shown that anti-CD4 antibodies immobilized on the walls of a microfluidic channel are sufficient to capture CD4+ T cells directly from whole blood, with high efficiency. In addition, controlled delivery of the low-volume whole blood sample and wash serves as a key feature in removing monocytes from the system, and improving the accuracy of the CD4 counting system. As both CD4+ T cell capture purity and yield are assured by the device, CD4 counts are accurately determined by simple enumeration of all retained cells from a know volume of blood sample using a standard light microscope, without the requirement of staining. The total assay time is less than 10 minutes.
We developed this CD4 counting microchip in the context of the emerging technology of microfluidics. Miniaturized lab-on-a-chip-type devices using microfluidics are extremely attractive for blood analysis, and have a growing impact in medical diagnostics and global health. 18 Demonstration in our study of cell analysis from unprocessed whole blood of HIV-infected subjects represents, to our knowledge, one of the first practical applications of microfluidics in blood cell diagnostics, and suggests new possibilities for microfluidic technology in global health and other end-user applications. 19 Currently, most absolute CD4 counts are obtained worldwide using flow cytometry.
However, flow cytometry is over-specified for the needs of global HIV programs. The extra capabilities of flow cytometry come at a price of expensive equipment, high operating costs, and the demand for technical skill. These demands have restricted the availability of CD4 testing in resource-poor settings. In Malawi, for instance, national program managers have chosen to forgo CD4 testing in most patients, largely because they lack the technical capacity to implement flow cytometry on a national scale.
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Similar challenges with existing technologies have been described throughout sub Saharan Africa, given limited laboratory infrastructure. 21, 22 Alternative approaches based on antibody-labeled magnetic beads eliminate sophisticated instruments, but still require multiple steps to handle blood samples and technical skill. Thus, they have proven to be labor intensive and time consuming, and have not been widely adopted.
The assay we describe here was designed based on the needs of the end user: health workers delivering ART-based HIV care in resource-poor settings. Thus, we aimed for simple and quick operation, and low equipment and assay cost. In terms of technical requirements, no sample preparation is necessary, and thus only minimal technical skill is needed to obtain a CD4 count. The assay is rapid, requiring only 10 minutes from blood collection to cell count.
In its current format, only two simple accessories, a pump and a basic light microscope, are needed for the entire assay, as specific and efficient capture of CD4+ T cells is realized by controlled shear force combined with affinity isolation. The microdevice is a self-contained system that uses a direct volumetric method and requires no labels, beads or other reagents, greatly reducing the operational cost and assay complexity. Only a small sample volume-ten microliters-is necessary, so that the assay could be performed with a fingerprick sample of blood, avoiding venipuncture and minimizing medical waste. These advantages make the assay feasible in remote settings with limited laboratory infrastructure, and would greatly expand the types of health facilities at which CD4 testing could occur.
From a technical perspective, the trade-off in making a cheap and simple assay is a slight decrease in assay performance. Accuracy drops off at CD4 counts above 800 cells/µL.
The sensitivity and specificity are only as high as ~90% at the clinically meaningful thresholds. Nonetheless, given the immediate need for simple CD4 counting technologies, we believe these are acceptable trade-offs, and enhance the implementation of CD4 testing and HIV care delivery in resource-poor settings.
Although the performance of the CD4 microdevice is less accurate than flow cytometry, particularly at high CD4 counts, the microdevice is not meant to replace flow cytometry.
Instead, the CD4 microdevice can distinguish useful thresholds for clinical decisionmaking and disease monitoring in resource-limited areas where labor-and instrumentintensive assays preclude the use of flow cytometry.
With additional engineering of embedded detection and control systems, it should be possible to create a push-button CD4 counting microdevice that can be carried and used at the point of care. The syringe pump in the current setup can be miniaturized by the incorporation of battery-operated microscale pressure regulators and micropumps.
Manual enumeration by light microscopy can be replaced with high-throughput optical, 23 electrical 24 or mechanical 25 sensors for automatic readout. Mass production of disposable assay chips using standard high-volume fabrication methods should make devices extremely inexpensive and cost-effective.
In summary, we demonstrate the performance of a simple, quick and inexpensive CD4+
T cell counting device. To our knowledge, this is the first design with which CD4 counts can be performed from a fingerprick sample of whole blood, without either sample processing or the addition of reagents. Minimum handling procedures, rapid operation, simple device design and potential high-throughput detection makes this strategy a promising candidate for managing HIV patients in resource-limited settings. We also note that CD4 counting is just one application for devices of this type. The demonstration of specific cell isolation with high efficiency using shear stress combined with cell affinity chromatography has the potential to be extrapolated to a number of applications where specific and efficient cell isolation is required. 
